Granules India announced a strong financial performance for the second quarter of fiscal year 2026 (Jul-Sep). Revenue from operations increased by 34% year-over-year to INR 12,970 Mn. EBITDA grew by 37% to INR 2,782 Mn, and Profit After Tax (PAT) also rose by 34% to INR 1,306 Mn, demonstrating robust growth and profitability.
Financial Highlights for Q2 FY26
Granules India Ltd. reported its financial results for the quarter ended September 30, 2025, showcasing significant growth across key metrics:
- Revenue from Operations: INR 12,970 Mn, a 34% increase compared to the same quarter last year.
- EBITDA (before exceptional items): INR 2,782 Mn, reflecting a 37% year-over-year growth.
- Profit Before Tax (PBT): INR 1,759 Mn, up by 37% compared to the previous year.
- Profit After Tax (PAT): INR 1,306 Mn, representing a 34% increase year-over-year.
Business Segment Performance
The revenue composition for Q2 FY26 is as follows:
- Finished Dosages (FD): Contributed 74% to the total revenue.
- Active Pharmaceutical Ingredients (API): Accounted for 13% of the revenue.
- Pharmaceutical Formulation Intermediates (PFI): Represented 10% of the revenue.
- Peptides/CDMO: Made up 2% of the total revenue.
Additional Financial Details
Other key financial metrics include:
- ROCE: Stands at 16.2% following the acquisition of Senn Chemicals AG.
- Net Debt: Recorded at INR 10,241 Mn.
- Net Debt to EBITDA ratio: 0.98x.
Management Commentary
Dr. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited, commented, “We are delighted to deliver a resilient financial performance with healthy growth in both revenue and profitability… Our peptides CDMO platform through Ascelis, anchored in the legacy of Senn Chemicals in Switzerland, is steadily gaining visibility, with renewed customer interest and promising new discussions underway.”
Source: BSE
